FindTrial
Sign In

MASCT-I

BIOLOGICAL4 trials

Sponsors

The First People's Hospital of Lianyungang, HRYZ Biotech Co.

Conditions

Advanced Gastric CancerAdvanced Solid TumorsAngiosarcomaDesmoplastic Small Round Cell TumorEndometrial Stromal SarcomaEpithelioid SarcomaFibrosarcomaLeiomyosarcoma

Phase 1

MASCT-I Treatment for Advanced Solid Tumor
NCT02858232
The First People's Hospital of LianyungangSolid Tumors
Start: 2016-08-31End: 2018-12-31Target: 46Updated: 2016-08-11
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
TerminatedNCT03034304
HRYZ Biotech Co.Advanced Solid Tumors
Start: 2017-02-22End: 2023-11-13Updated: 2025-07-24
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
NCT03393416
HRYZ Biotech Co.Advanced Gastric Cancer
Start: 2018-04-19End: 2020-07-31Target: 28Updated: 2019-08-29

Phase 2

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
RecruitingNCT06277154
HRYZ Biotech Co.Angiosarcoma, Desmoplastic Small Round Cell Tumor, Endometrial Stromal Sarcoma +8
Start: 2024-02-21End: 2027-02-28Target: 148Updated: 2025-07-24

Related Papers

Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial.
2026-08-03
Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.
Journal of Clinical Oncology2024-06-01
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).
Journal of Clinical Oncology2023-06-01
A phase I study to evaluate the safety of multiantigen stimulated tumor specific cell therapy (MASCT-I) in subjects with advanced gastric cancer.
Journal of Clinical Oncology2021-01-203 citations
Safety and efficacy of PD-1 blockade-activated multiple antigen specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials.
Journal of Clinical Oncology2019-05-204 citations